Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | HTT | P42858 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.68 |
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | ATM | Q13315 | 5/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | MITF | O75030 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | NSD2 | O96028 | 3/20 | 0.60 |
| ▸ | CDC25A | P30304 | 3/20 | 0.60 |
| ▸ | CDC25B | P30305 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31682570 | 0.84 | RAB9A (0.62) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL7240445 | 0.82 | MAPT (0.74) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL32664539 | 0.82 | MAPT (0.79) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL6506683 | 0.81 | MAPT (1.00) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL29633261 | 0.81 | MAPT (1.00) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL2241314 | 0.81 | KMT2A (0.71) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL2241802 | 0.79 | MAPT (0.58) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL8663288 | 0.79 | MAPT (0.74) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL4873496 | 0.79 | MAPT (1.00) | MAPTHTTKMT2ARAB9ANPSR1 | |
| SCHEMBL4868219 | 0.79 | MAPT (1.00) | MAPTHTTKMT2ARAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | MAPT 4401/4885HTT 1280/4885KMT2A 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.